The activation of tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAIL-R2)/death receptor 5 (DR5) induces apoptosis in various tumor cells but not in normal human cells. Because some therapeutic antibodies targeting TRAIL-R2 have demonstrated severe hepatotoxicity in clinical applications, novel in vivo models reflecting clinical hepatotoxicity are now required. In this study, we investigated the hepatotoxicity caused by KMTR2, an anti-human TRAIL-R2 monoclonal antibody, in chimeric mice with humanized livers (PXB-mice). PXB-mice were exposed to KMTR2 by single or repeated (weekly for 4 weeks) intravenous administrations, and the analyses of blood chemistry, liver histopathology, hepatic gene expression, and toxicokinetics were performed. Treatment with 1 or 10 mg/kg of KMTR2 increased alanine transaminase (ALT) activity and human ALT1 levels in blood. Histopathological analysis revealed that cell death and degeneration with the infiltration of inflammatory cells in human but not mouse hepatocytes were increased in a timedependent manner after KMTR2 administration. Furthermore, increases in TdT-mediated dUTP nick end labeling (TUNEL)-positive human hepatocytes and serum concentration of cleaved cytokeratin 18, a human-specific apoptosis marker, were observed. RNA sequence analysis showed that the gene expression profile changed in different manners between human and mouse hepatocytes and the up-regulation of TRAIL-R2-related genes was observed only in human hepatocytes. Taken together, these results indicate that KMTR2-mediated TRAIL-R2 activation induces apoptosis of human hepatocytes and hepatotoxicity in PXB-mice and suggest that chimeric mice with humanized liver can be novel tools for the evaluation of in vivo human-specific hepatotoxicity induced by therapeutic antibodies in pre-clinical studies.
induces apoptosis in various human tumor cell lines as well as in tumor xenograft models but not in the majority of normal human cells in pre-clinical studies (Ashkenazi et al., 1999) , TRAIL and its receptor-targeted therapy can be a novel strategy for the treatment of tumors. Although recombinant human TRAIL and agonistic antibodies against TRAIL-R1 and TRAIL-R2 have been developed, none of these has yet produced clinical benefit for cancer patients, mainly due to insufficient activity or severe hepatotoxicity (Von Karstedt et al., 2017) . The potential hepatotoxicity of TRAIL has been of great interest as the systemic administration of TNF-a was found to cause severe liver dysfunction in humans (Schilling et al., 1992) and treatment with Fas agonistic antibody immediately killed mice due to severe liver damage by apoptosis (Ogasawara et al., 1993) . In addition, the anti-TRAIL-R2 agonistic antibody lexatumumab and tetravalent agonistic nanobody TAS266 have induced severe hepatotoxicity in clinical trials (Papadopoulos et al., 2015; Plummer et al., 2007) .
Several pre-clinical experimental models have been used to evaluate the toxicity of several forms of TRAIL and its receptortargeted antibodies to elucidate the association of direct agonistic activity against TRAIL-R2 with the hepatotoxicity. As an in vitro model, primary human hepatocytes (PHHs) have been reported to undergo apoptosis when incubated with a polymerizable polyhistidine-tagged form or a cross-linked FLAG-tagged form of human TRAIL, but not with a non-tagged TRAIL or TAS266 (Ichikawa et al., 2001; Lawrence et al., 2001; Papadopoulos et al., 2015) . Because it was reported that the TRAIL sensitivity of PHHs depended on the culture conditions of hepatocytes (Ganten et al., 2006) , whether or not the TRAILinduced cytotoxicity observed in PHHs in vitro can be extrapolated to in vivo situations remains controversial. In in vivo models, no TRAIL agonists (a non-tagged TRAIL, a tagged TRAIL, and TAS266) have shown hepatotoxicity in mice, rats, or cynomolgus monkeys (Kelley et al., 2001; Papadopoulos et al., 2015; Walczak et al., 1999) . These results have raised the possibility that human hepatocytes are uniquely susceptible to TRAILmediated apoptosis compared with rodent and non-human primate hepatocytes. Therefore, novel in vivo models reflecting the TRAIL-induced human-specific hepatotoxicity in clinical settings are required.
Chimeric mice with humanized liver (hereafter referred as chimeric mice) may be useful tools for evaluating such humanspecific hepatotoxicity under in vivo conditions. The PXBmouse, one of the chimeric mice reported thus far, is generated by transplanting human hepatocytes into severe combined immunodeficiency (SCID) mice with liver failure induced by urokinase-type plasminogen activator gene (uPA/SCID or cDNAuPA/SCID mice) . In PXB-mice, the host mouse hepatocytes are highly replaced with human hepatocytes, which express a variety of human mRNA and proteins including albumin, drug-metabolizing enzymes, and transporters (Katoh et al., 2004 (Katoh et al., , 2005 Nishimura et al., 2005) . Importantly, the gene expression profile of PXB-mice is extremely similar to that of normal human liver in situ (Tateno et al., 2013) . These mice have been used in studies on the infection of human hepatitis B and C viruses and drug metabolism and disposition for more than a decade (Kosaka et al., 2013; Lü tgehetmann et al., 2012; Sanoh et al., 2015) . Recently these chimeric mice have been considered useful for the detection of hepatotoxicity induced by representative small-molecule drugs (eg, acetaminophen, troglitazone, and fialuridine). However, the potential utility of chimeric mice for evaluating the safety of therapeutic antibodies remains to be explored Kakuni et al., 2012; Schulz-Utermoehl et al., 2012; Xu et al., 2014; Yamamoto et al., 2007) .
KMTR2 is a human monoclonal antibody against human TRAIL-R2. This antibody acts as a direct agonist possessing a strong ability to induce apoptosis, but is not toxic to cynomolgus monkey (Motoki et al., 2005) . In this study, to evaluate the potential hepatotoxicity caused by TRAIL-R2 agonists in PXBmice, we treated PXB-mice with KMTR2, and analyses of the blood chemistry, liver histopathology, hepatic gene expression, and toxicokinetics.
MATERIALS AND METHODS
Test articles. Recombinant human TRAIL/TNFSF10 (rhTRAIL, histidine-tagged extracellular domain) and recombinant human FasL (rhFasL) were purchased from R&D Systems (Minneapolis, Minnesota). Control antibody and KMTR2 were prepared internally (Motoki et al., 2005) .
Cell culture and viability assay. Freshly isolated PHHs (fresh-PHHs) from four donors, cryopreserved PHHs (cryo-PHHs) from two donors, and PXB-cells were obtained from Biopredic International (Rennes, France), Bioreclamation-IVT (Baltimore, Maryland), and PhoenixBio (Higashihiroshima, Japan), respectively. Fresh-PHHs were cultured in long-term culture medium (Biopredic International), and cryo-PHHs and PXB-cells were cultured in CP medium (Bioreclamation-IVT). Cells were cultured in 96-well plates, and the cell viability was evaluated by a WST-8 colorimetric assay (Cell Counting Kit-8; Dojindo Laboratories, Kumamoto, Japan) after 5-to 6-day treatment with the test articles. The absorbance of 450/620 nm (absorbance at 450 nm minus the absorbance at 620 nm) was defined as the viability of the cells.
Animals. All PXB-mice used in this study were transplanted with frozen human hepatocytes derived from a single donor (BD Biosciences, Woburn, Massachusetts) and used after the confirmation of liver humanization (!70%) by the presence of human albumin (!7.0 mg/ml) in blood. Humanization ratio and baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities of PXB-mice used are summarized in Supplementary Figure 1 . SCID mice (Fox Chase SCID C.B-17/Icrscid/scid Jcl) were purchased from CLEA Japan (Tokyo, Japan). Male mice at 12-15 weeks old at dosing were maintained on an irradiation-sterilized pellet diet for rodents and tap water ad libitum under a 12-h light-dark cycle.
Ethics statement. All animal experiments were performed in accordance with the Company Policy on the Care and Use of Laboratory Animals (Kyowa Hakko Kirin) with ethical approval of the PhoenixBio Ethics Board.
Animal study and sample collection. KMTR2 was diluted with vehicle (1.8% glycine, 1.0% sucrose, 0.02% w/v polysorbate 80, pH 6.5) at 0.2 or 2 mg/ml. The mice were held in a restraint, and KMTR2 or the vehicle was injected via tail vein at a rate of 50 ll/s using a disposable syringe and either a needle or a butterfly needle. The mortality and body weight were monitored during the study. Blood was collected sequentially from orbital venous plexus (PXB-mice) or tail vein (SCID mice) using microhematocrit capillary tubes, and the serum (PXB-mice) or plasma (SCID mice) was obtained by centrifugation. At necropsy, all mice were euthanized by exsanguination under isoflurane anesthesia. The livers were quickly excised and weighed and then rapidly frozen in liquid nitrogen or fixed in 10% formalin.
Blood analyses. Collected blood was diluted with saline and centrifuged (390 Â g, room temperature), and the supernatant was used for the measurement of the human albumin concentration by the latex agglutination and turbidimetry method. The activities of ALT and AST were measured by the pyruvate oxidaseperoxidase leuco dye method (for PXB-mice) or the modified JSCC method (for SCID mice). The human-specific ALT1 concentration was measured by an enzyme-linked immunosorbent assay (ELISA) system as previously described in Tateno et al. (2014) . The KMTR2 concentration in serum was determined by an electrochemiluminescent immunoassay using the following internally prepared antibodies: biotinylated anti-human IgG antibody, HRP-labeled anti-human IgG, and ruthenylated anti-HRP antibody. Electrochemiluminescent signals were detected using a SECTOR Imager 2400 (Meso Scale Discovery, Gaithersburg, Maryland). The lower limit of quantification was set to be 30 ng/ ml. The M30-Apoptosense ELISA kit (VLVbio, Sundbyberg, Sweden) was used to detect cleaved cytokeratin 18 (cCK18) in serum. Samples were diluted with buffer and internally prepared pooled SCID mouse serum to contain 10% mouse serum, and the cCK18 concentration was determined according to the manufacturer's protocol. If the measured concentration was below the lower limit of detection (20 U/l), the value was regarded as 20 U/l. Fold-changes in each item were expressed as the ratios of the values after KMTR2 treatment to those before KMTR2 administration.
Liver histopathology. Fixed livers obtained from all PXB-mice were embedded in paraffin and sectioned. The sections stained with hematoxylin and eosin were examined microscopically to observe the morphological changes in the liver. Each specimen was graded according to the following criteria: À, non-remarkable; 1þ, very slight; 2þ, slight; 3þ, moderate; 4þ, marked. For immunohistochemistry, monkey-absorbed antihuman IgG heavy and light chain antibody (Bethyl Laboratories, Montgomery, Texas) and anti-MHC class I þ HLA A þ HLA B antibody (Abcam, Cambridge, Massachusetts) were used. Immunoreactivity was visualized by 3,3-diaminobenzidine colorimetric reaction, and all of the sections were counterstained with hematoxylin. For the TdT-mediated dUTP nick end labeling (TUNEL) assay, an ApopTag Peroxidase In Situ Apoptosis Detection Kit (Merck Millipore, Darmstadt, Germany) was used according to the manufacturer's protocol. For the quantitative analysis of TUNEL in human hepatocytes, stained sections were scanned digitally with a ScanScope XT system (Aperio Technologies, Vista, California). The ratio of TUNEL-positive nuclei in human hepatocyte areas was determined using the ScanScope software program (Aperio Technologies).
RNA isolation, RT-PCR, and RNA-sequence analysis. Total RNA was extracted from the liver of PXB-and SCID mice in the singledose study using the AllPrep DNA/RNA Mini Kit (QIAGEN, Hilden, Germany). Sequence library was constructed with TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, California) and Agilent XT-Auto System (Agilent Technologies, Santa Clara, California). A next-generation sequencer (HiSeq 2500; Illumina) and HiSeq SBS Kit v4-HS (Illumina) were used for sequencing. Sequence reads were analyzed using CLC Genomics Workbench 8.5.1 (QIAGEN). The reads were mapped to human and mouse reference genomes GRCh37.73 and GRCm37.67, respectively. Analysis was conducted using GeneSpring Workgroup 14.5, Microsoft Office Excel 2010 (Microsoft, Redmond, Washington), and Ingenuity Pathway Analysis (IPA, Spring 2015 version; QIAGEN), and TIBCO Spotfire 7.5.1 (TIBCO Software, Palo Alto, California). The sequence data have been deposited in DNA Data Bank in Japan (DDBJ) under the accession number DRA006796. For quantitative reverse transcription-polymerase chain reaction (RT-PCR), cDNA was synthesized using SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, California). Quantitative real-time PCR was carried out using 7900HT Fast real-time PCR system and PowerUp SYBR Green Master Mix (Applied Biosystems, Waltham, Massachusetts). The mRNA levels were normalized to those of HPRT1 for human genes or Hprt for mouse genes. The primers used for the amplification are listed in Supplementary  Table 1 .
Statistical analysis. All data are expressed as mean 6 standard deviation (SD) or individual values. Statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina) for Student's t test, and a p value < .01 was considered statistically significant.
RESULTS

In vitro Study Using Three Types of PHHs
We first investigated whether KMTR2 and rhTRAIL could induce hepatotoxicity in vitro using several types of human hepatocytes: fresh-PHHs, cryo-PHHs, and PXB-cells (human hepatocytes freshly isolated from PXB-mice). None of the test articles decreased the cell viability of the fresh-PHHs from two donors ( Figure 1A ), but treatment with the positive control rhFasL induced substantial cell death of fresh-PHHs from another two donors ( Figure 1B ). In contrast, both KMTR2 and rhTRAIL partially decreased the cell viability of cryo-PHHs from two donors ( Figure 1C ) and PXB-cells ( Figure 1D ). These results indicated that the sensitivity to the TRAIL-R2 signal of human hepatocytes depends on the type or condition of the hepatocytes. Therefore, in vitro cultured hepatocytes appear to be unsuitable for evaluating the safety of TRAIL-R2 agonists.
Four-week Repeated-dose Administration of KMTR2 in PXB-mice To investigate whether hepatotoxicity could be observed with KMTR2 treatment in PXB-mice, KMTR2 at 1 and 10 mg/kg was repeatedly administered to PXB-mice intravenously once weekly for 4 weeks (Figure 2A ). Whereas no changes in the mortality or body weight gain due to KMTR2 treatment were observed (data not shown), elevations in the serum ALT and AST activities induced by KMTR2 were observed from the first dosing, except for in one mouse in the group receiving 10 mg/kg KMTR2 ( Figure 2B and Supplementary Figure 2) . Because human hepatocytes in the chimeric mice have the morphological feature of steatosis, we performed a correlation analysis between ALT activities at baseline (without treatment) and those at necropsy (after KMTR2 treatment) to assess whether the baseline liver status was associated with the extent of KMTR2-induced liver injury. As indicated in Supplementary Figure 3 , there was no statistical association between the elevated ALT activity after KMTR2 treatment and the baseline ALT activity.
The liver tissues obtained from these mice were then histopathologically evaluated. Figures 2C and 2D show representative images of the liver sections of the vehicle-treated PXB-mice. The human hepatocytes were able to be easily distinguished from the areas of mouse hepatocytes by their whitish color with diffuse vacuolation composed of macrovesicular and microvesicular changes (Tateno et al., 2013) . A morphological analysis of the liver sections revealed that KMTR2 induced an increase in the hepatocellular degeneration with the infiltration of inflammatory cells ( Figure 2E ), except for the aforementioned mouse in the 10 mg/kg group showing no elevation in ALT activity. These changes were observed in the areas consisting of human hepatocytes but not of mouse hepatocytes ( Figure 2F) .
A toxicokinetic analysis showed that the serum concentration of KMTR2 remained constant during the study in all mice, and KMTR2 showed linear pharmacokinetics ( Figure 2G ). Positive human-IgG staining, which reflects the distribution of administered KMTR2, was observed in the sinusoid and blood vessels of both areas of human and mouse hepatocytes in KMTR2-treated PXB-mice ( Figure 2H ). These results suggest that intravenously administered KMTR2 was distributed in the whole liver, but induced degeneration and cell death accompanied by inflammatory cell infiltration only in human hepatocytes of PXB-mice.
Single-dose Administration of KMTR2 in PXB-mice To assess the mechanism of hepatotoxicity caused by KMTR2, PXB-mice were treated with a single-dose of KMTR2, and the time-course of liver toxicity was investigated ( Figure 3A) . No marked changes in the mortality or body weight gain were observed. As shown in Figure 3B and Supplementary Figure 2 , a clear elevation in the ALT and AST activities and an increase in the human ALT1 concentrations was observed within 24 h after KMTR2 administration, and reached its maximum 48 h after the administration, except for in one mouse. As shown in Supplementary Figure 3 , there was no statistical association between the elevated ALT activity after KMTR2 treatment and the baseline ALT activity. In liver tissues, immunostaining with anti-human MHC antibody was performed to distinguish human hepatocytes from host mouse hepatocytes for further analysis ( Figure 3C ). An increase in the extent of single cell death and degeneration with an infiltration of inflammatory cells (Figs. 3C-E) was observed from 48 h after KMTR2 administration and was more remarkable at 168 h, except for in the mouse treated with KMTR2 that exhibited no increase in the ALT activity or human ALT1 concentration. These changes were observed in the areas consisting of human hepatocytes, not in the mouse hepatocyte area. In addition, the ratio of TUNEL-positive nuclei was increased in the human hepatocyte areas of KMTR2-treated mice (Figs. 4A and 4B ). The concentration of serum cCK18, which is a blood marker of human-specific apoptosis, was clearly elevated from 48 h after KMTR2 administration, and the elevation continued through 168 h, except for in the mouse that exhibited no hepatotoxicity ( Figure 4C) . A strong correlation between cCK18 and the human ALT1 concentrations was observed ( Figure 4D ).
To confirm that KMTR2 had no effect on mouse hepatocytes, KMTR2 was administered intravenously to SCID mice, and the blood ALT activity was evaluated. No test article-related changes of ALT and AST were observed (Supplementary Figure 4) . These results strongly suggest that KMTR2 induces cellular apoptosis only in human hepatocytes and not in mouse hepatocytes.
RNA Sequence Analysis of the Liver in the Single-Dose Study
To clarify the molecular events related to the hepatotoxicity caused by KMTR2, RNA sequence analysis was performed with the liver samples of PXB-mice and SCID mice in the single-dose study. Because RNA extracted from the liver of PXB-mice contained both human and mouse mRNA, we performed a two-step mapping to count each species-specific sequences Figure 2 . Four-week repeated-dose study with KMTR2 using PXB-mice. A, A schematic illustration of the study design is shown. PXB-mice were intravenously administered with 1 or 10 mg/kg KMTR2 weekly for 4 weeks (n ¼ 4 per group), and blood and liver tissues were collected. B, The serum ALT activities were determined and are shown individually as fold-change values compared with those at pre-dosing. C and D, Liver sections were stained with hematoxylin and eosin, and representative images of vehicle-treated mice at Â1.25 (C) or Â10 (D) magnification are shown. The scale bars indicate 1 mm (C) and 100 lm (D). E and F, Representative images from 1 mg/kg KMTR2-treated PXB-mice at Â20 magnification are shown. The degenerative change is observed only in human hepatocyte area (E) but not in mouse hepatocyte area (F). The scale bar indicates 100 lm. G, The serum concentrations of KMTR2 are presented as mean 6 SD (n ¼ 4). H, The liver sections were stained with anti-human IgG and representative images from 10 mg/kg KMTR2-treated PXB-mice at Â20 magnification are shown. The areas of human hepatocytes (left) and mouse hepatocytes (right) are presented. The scale bars indicate 100 lm.
( Figure 5A ). To obtain information of human gene expression, all reads were mapped to mouse reference genome at the first step, and both broken-reads, which were mapped only on one side of the paired end, and unmapped-reads, which were not mapped to either of the pair ends, were acquired. Subsequently, these reads were mapped to human reference genome as the second step, and the reads per kilobase of exon per million mapped reads (RPKM) of the human-specific reads were calculated. Gene expression profiles of mouse hepatocytes were also calculated by the similar procedure. The number of unique human and mouse Ensembl gene IDs was 16458-17132 and 16292-16986, respectively (Supplementary Table 2 ). The RPKM of Figure 3 . Single-dose study using PXB-mice. A, A schematic illustration of the study design is shown. PXB-mice were intravenously administered with 1 mg/kg KMTR2 by a single injection (n ¼ 3 per group), and blood and liver tissues were collected as indicated. B, The serum ALT activities (left) and human ALT1 concentrations (right) were determined and are shown individually as fold-change values compared with those at pre-dosing. C, The liver sections were stained with hematoxylin and eosin (left) or anti-human MHC (right) and representative images of the sections from KMTR2-treated PXB-mice (168 h after administration) at Â20 magnification are shown. human TNFRSF10B (encoding TRAIL-R2) was more than 10, suggesting that TRAIL-R2 was expressed in the human hepatocytes of all the PXB-mice used in this study ( Figure 5B) . Next, we selected the genes whose expression in TRAIL-R2-treated mice was 1.5-fold higher or lower than the median expression in the vehicle-treated mice (Supplementary Table 2 ). These genes were subjected to a Diseases and Functions Analysis of IPA ( Figure 5C ). The results indicate that the cell cycle-related functions were up-regulated only in human hepatocytes, whereas the inflammatory response and immune cell trafficking-related functions were up-regulated only in mouse hepatocytes. These changes were not observed in SCID mice treated with KMTR2.
To investigate the association between the changes in the gene expression profiles and KMTR2-induced hepatotoxicity, we selected 292 human genes for Network Analysis of IPA. The genes were selected according to the following criteria: (1) genes whose expressions were not changed in the liver of mice exhibiting no hepatotoxicity (vehicle-treated mice and the one mouse treated with KMTR2 showing no hepatotoxicity), (2) genes whose expressions showing more than 2-fold changes in mice with hepatotoxicity (KMTR2-treated), and (3) genes whose mouse orthologs showed no change in their expressions in any mice. Interestingly, some of the genes selected were associated with TNFRSF10B ( Figure 6A ), among which CXCL10, CCL20, and CXCL8 have been reported to be up-regulated upon TRAIL-R2 activation in vitro (Nguyen et al., 2009; Tang et al., 2009; Wang et al., 2010; Weckmann et al., 2007) . To confirm these results, mRNA levels of the human genes and their mouse orthologs (except CXCL8, which is a human-specific gene with no mouse ortholog) were determined by quantitative RT-PCR ( Figure 6B ). Levels of mRNA of all human genes investigated, but not those of the mouse orthologs, were higher in the liver of mice showing hepatotoxicity (KMTR2-treated mice except for the one mouse with no hepatotoxicity) than in control mice. These results suggest that KMTR2 induces the activation of TRAIL-R2 signal specifically in human hepatocytes and not in mouse hepatocytes.
DISCUSSION
To the best of our knowledge, this is the first report to demonstrate the toxicity to human hepatocytes of a therapeutic antibody in an experimental in vivo model of normal human hepatocytes. The results of our study indicate that the agonistic antibody KMTR2 directly induced apoptosis of human hepatocytes in PXB-mice via its agonistic activity. The KMTR2-mediated hepatotoxicity was confirmed by significant increases in the serum ALT and human ALT1 levels as well as based on the observations of single cell death and hepatocellular degeneration with the infiltration of inflammatory cells in the histopathological analysis. The increases in the number of TUNELpositive cells and cCK18 concentrations in blood suggest the apoptosis-mediated cell death of human but not mouse hepatocytes.
In a previous study, the administration of a non-tagged form of TRAIL to chimeric mice with humanized liver did not induce hepatotoxicity (Hao et al., 2004) , which seems to conflict with our results. In addition, in the recent clinical trial of dulanermin, a non-tagged form of TRAIL, with a chemotherapeutic agent, no severe hepatotoxicity was observed, and the overall survival of non-small cell lung carcinoma patients was not improved (Herbst et al., 2010; Ouyang et al., 2018) . These contradictory results might be explained by differences in the agonistic activities of non-tagged TRAIL and KMTR2. KMTR2 has a much stronger agonistic activity against TRAIL-R2 than nontagged TRAIL (Motoki et al., 2005) .
In the RNA sequence analysis of both human and mouse genes, we showed the up-regulation of TRAIL-R2-related genes only in human hepatocytes. This suggests that KMTR2 activates TRAIL-R2 signal selectively in human hepatocytes. The Diseases and Functions Analysis of IPA showed that the cell cycle-related functions were up-regulated in human hepatocytes, which might be an adaptive response of regeneration after cell death of human hepatocytes. In mouse hepatocytes, the inflammatory response and immune cell trafficking-related functions were up-regulated, which is in line with the results of the histopathological analysis, in which mouse inflammatory cells (eg, neutrophils or macrophages) infiltrated into the liver in response to the death of human hepatocytes induced by KMTR2. There is a limitation of this analysis because mouse RNA is derived from not only hepatocytes but also hepatic non-parenchymal cells (eg, sinusoidal endothelial cells, Kupffer cells, and infiltrated immune cells) whereas human RNA is derived from only parenchymal hepatocytes. Nonetheless, the results strongly support the idea that KMTR2 induces the apoptosis of human hepatocytes, and thus this kind of analysis might be a practical way of understanding the status of human hepatocytes in the liver of chimeric mice. Some controversial results have been reported regarding the effects on in vitro cultured PHHs. In this study, we used three types of human hepatocytes, fresh-PHHs, cryo-PHHs, and PXBcells, and found that KMTR2 and histidine-tagged rhTRAIL, which was regarded as toxic in freshly isolated PHHs in a previous study (Jo et al., 2000; Lawrence et al., 2001) , were toxic to cryo-PHHs and PXB-cells but not fresh-PHHs. Another report showed that highly polymerizable recombinant TRAIL-induced apoptosis of freshly isolated PHHs at day 1 but not at day 4 of in vitro culture (Ganten et al., 2006) . This is consistent with our results, as in this study, fresh-PHHs were exposed to TRAIL agonists after approximately one week's culture from isolation and showed no toxicity. These results suggest that the sensitivity to TRAIL agonists depends largely on the conditions of human hepatocytes and that in vitro systems are not suitable for evaluating the toxicity of TRAIL agonists.
Small molecule drugs often induce human-specific liver injury and chimeric mice have been used to evaluate such liver injury (Kakuni et al., 2012; MacDonald and Robertson, 2009; Xu et al., 2014; Yamamoto et al., 2007) . Some therapeutic antibodies also induce liver injury in clinical settings (Tamaki et al., 2013) . Therapeutic antibody-mediated toxicity is usually caused by its on-target effects, but pre-clinical information on the potential toxicity is often limited due to the species differences between human and experimental animals in the affinity of antibodies to target proteins and sensitivity to induce antibody-mediated signals (Hansel et al., 2010) . In the case of TRAIL agonistic antibodies, human hepatocytes in chimeric mice seem to be susceptible to TRAIL-mediated apoptosis even though KMTR2 and TAS266 were not found to be hepatotoxic in cynomolgus monkeys (Papadopoulos et al., 2015) . Furthermore, the liver of chimeric mice expresses most genes at levels similar to those in normal human livers (Tateno et al., 2013) . Therefore, chimeric mice may be suitable models for predicting human hepatotoxicity of not only small-molecule drugs but also therapeutic antibodies.
The extent of TRAIL-induced apoptosis in hepatocytes depends on the disease status. Cholestasis sensitizes the liver to TRAIL-induced hepatotoxicity in bile duct-ligated mice (Higuchi et al., 2002) . Furthermore, liver explants in organotypic culture from patients with steatosis or HCV infection were more susceptible to TRAIL hepatotoxicity than those from healthy subjects (Volkmann et al., 2007) . PXB-mice show a gene expression profile similar to healthy humans, but the accumulation of lipid droplets is often observed in human hepatocytes in PXBmice. Therefore, whether or not the sensitivity to TRAIL in human hepatocytes of PXB-mice is enhanced due to lipid accumulation remains to be clarified.
One of 4 mice treated with 10 mg/kg KMTR2 for 4 weeks did not show an elevation of serum ALT activity or histopathological liver injury. In the single-dose study, one mouse exposed to 1 mg/kg KMTR2 also did not show hepatotoxicity, and the expression of TRAIL-R2-related genes was not changed in this mouse. The PXB-mice used in this study had human hepatocytes derived from the same single donor, and the humanization ratio of the liver, baseline activities of ALT and AST, and morphological features of the mice were not markedly different from those of other mice. Furthermore, the distribution of KMTR2 in the mouse that exhibited no hepatotoxicity in the repeated-dose study was within the normal range, and the TRAIL-R2 expression was confirmed in the single-dose study. In contrast, only a weak increase in the cCK18 concentration was observed at 48 h after the administration in the mouse. These results suggest that KMTR2 treatment may have rapidly induced the apoptosis of human hepatocytes in this mouse, but this effect did not continue until 168 h after administration. The limitation of this study is that the sample size is small and no statistical analysis because of the availability of the chimeric mice and the inter-individual variations aforementioned. Further experiments using a greater number of chimeric mice, which enables us to perform statistical analysis, and chimeric mice with human hepatocytes derived from other donors will be needed to confirm our results as well as for elucidating donor-to-donor variability and the reason for the occurrence of non-responders.
Recent pre-clinical and clinical results have suggested that anti-drug antibody (ADA) affects the agonistic activity of TRAIL agonists. The administration of dulanermin to cynomolgus monkeys induced the production of ADAs due to the fouramino acid differences between human and monkey TRAIL (Zuch de Zafra et al., 2016) . This ADA strengthened the agonistic activity of dulanermin, leading to severe hepatotoxicity. Furthermore, TAS266 induced severe hepatotoxicity in three out of four patients in clinical trial (Papadopoulos et al., 2015) , possibly due to pre-existing ADAs increasing the agonistic activity of TAS266 (Von Karstedt et al., 2017) . In our study, ADAs do not seem to be involved in the hepatotoxicity, as PXB-mice were generated from cDNA-uPA/SCID mice, which are defective in functional T and B lymphocytes and thus might not produce ADAs (Bosma et al., 1983) .
TRAIL is regarded as an important player not only in cancer treatment but also in inflammatory responses. The interaction of TRAIL and TRAIL-Rs induces NF-kB activation and thus the production of a variety of cytokines and chemokines (Tang et al., 2009) , some of which are involved in the drug-induced liver injury (Adams et al., 2010) . Because TRAIL-Rs are expressed in regulatory T cells and myeloid-derived suppressor cells, the agonistic effects of TRAIL against these immune-related cells might contribute to the TRAIL-mediated hepatotoxicity (Condamine et al., 2014; Diao et al., 2013) . Unfortunately, the effects of KMTR2 on immune cells cannot be evaluated in chimeric mice because KMTR2 does not cross-react with mouse TRAIL-R2. Recently, the generation of a human peripheral blood mononuclear cells-injected (immune-humanized) chimeric mouse model with humanized liver was reported (Okazaki et al., 2012; Uchida et al., 2015) . This model might be useful for investigating the role of immune-related factors in the TRAILassociated hepatotoxicity.
In conclusion, our results suggest that the KMTR2-mediated TRAIL-R2 activation induces the apoptosis of human hepatocytes and hepatotoxicity in PXB-mice. The possible adverse effects of TRAIL agonists against normal cells, such as hepatocytes, must be minimized, and clinical trials of TRAIL agonists should be performed carefully if its agonistic activities are enhanced compared with that of the native form of TRAIL. Chimeric mice with humanized liver such as PXB-mice can be novel tools for the evaluation of the in vivo human-specific hepatotoxicity induced by therapeutic antibodies in preclinical studies to minimize safety concerns in subsequent clinical tests.
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